Pyxis Oncology Inc.

1.08
0.00 (0.00%)
At close: Apr 24, 2025, 3:59 PM
1.09
0.84%
After-hours: Apr 24, 2025, 07:33 PM EDT
0.00%
Bid 1.02
Market Cap 66.52M
Revenue (ttm) 16.15M
Net Income (ttm) -77.33M
EPS (ttm) -1.4
PE Ratio (ttm) -0.77
Forward PE -0.92
Analyst Buy
Ask 1.21
Volume 278,311
Avg. Volume (20D) 587,239
Open 1.06
Previous Close 1.08
Day's Range 1.03 - 1.09
52-Week Range 0.83 - 5.39
Beta 1.17

About PYXS

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol PYXS
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 825.93% from the latest price.

Stock Forecasts
1 month ago
-5.83%
Pyxis Oncology shares are trading higher after the... Unlock content with Pro Subscription
5 months ago
-45.03%
Pyxis Oncology shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform.